Damora Therapeutics (DMRA) Accumulated Expenses (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Accumulated Expenses data on file, last reported at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 401.0% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 401.0% YoY), and the FY2025 full-year result was $2.4 million, up 192.8% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.0 million, up from $2.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.5 million in Q1 2023 and bottomed at $820000.0 in Q4 2024.
• The 5-year median for Accumulated Expenses is $4.0 million (2022), against an average of $4.6 million.
• The widest annual swing landed in 2024, when Accumulated Expenses slumped 80.14%; it then soared 401.0% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $7.8 million in 2022, then slumped by 46.78% to $4.1 million in 2023, then plunged by 80.14% to $820000.0 in 2024, then jumped by 192.8% to $2.4 million in 2025, then surged by 149.77% to $6.0 million in 2026.
• The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.

Peer Comparison